Human PD-1 enzyme-linked immunoassay kit

CAT: EH0062 Datasheet
Specification 96 Test
Sensitivity 0.05 pg/ml (50 μl);1.64 pg/ml (10 μl)
Standard Curve Range 1.37~1000 pg/ml
Standard Curve Gradient 7 Points/3 Folds
Number of Incubations 2
Sample Volume 50 μl/10 μl
Type Fully Ready-to-Use
Operation Duration 120min
pg/ml O.D. Average Corrected
0.00 0.0150 0.0143 0.0147
1.37 0.0296 0.0294 0.0295 0.0149
4.12 0.0578 0.0573 0.0576 0.0429
12.35 0.1454 0.1387 0.1421 0.1274
37.04 0.3980 0.3963 0.3972 0.3825
111.11 1.1110 1.1360 1.1235 1.1089
333.33 2.6150 2.5850 2.6000 2.5854
1000.00 4.1695 4.1661 4.1678 4.1532

Precision

Intra-assay Precision Inter-assay Precision
Sample Number S1 S2 S3 S1 S2 S3
22 22 22 6 6 6
Average(pg/ml) 29.9 126.7 422.8 25.1 108.9 326.8
Standard Deviation 1.6 6.3 25.8 1.8 6.3 16.2
Coefficient of Variation(%) 5.3 5.0 6.1 7.2 5.8 4.9

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.

Spike Recovery

The spike recovery was evaluated by spiking 3 levels of human PD-1 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 82% to 108% with an overall mean recovery of 95%.

Sample Values

Sample Matrix Sample Evaluated Range (pg/ml) Detectable (%) Mean of Detectable (pg/ml)
Serum 30 90.86-174.38 100 130.26

Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of PD-1 in this assay. No medical histories were available for the donors.

Background: PD-1

PD-1 (Programmed Death-1 receptor) is a key regulator of the threshold of immune response and peripheral immune tolerance. It is expressed on activated T cells, B cells, monocytes, and dendritic cells and binds to PD-L1 or PD-L2. PD-1 ligation induces co-inhibitory signals in T cells promoting their apoptosis, anergy, and functional exhaustion. Blockade of the PD-1: PD-L1 interaction using anti-PD-1 antibodies enhances understanding of anti-tumor immunity and advances the potential for cancer immunotherapy.

Under construction!

Under construction!

Under construction!

Contact Information
Related Products
相关途径
Guarantee